Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.
Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.
Feature Symposium. Stephen Strom, Karolinska Institutet, Stockholm, Sweden. Luc van der Laan, Erasmus Medical Center, Rotterdam, the Netherlands. Alberto Sanchez-Fueyo, King’s College Hospital, London, UK. David Hay, University… read more.
Report from the Joint International Congress of ILTS, ELITA and LICAGE 2014. Recurrence of hepatitis C virus (HCV) infection after transplantation is a major challenge for centres all… read more.
Report from the Joint International Congress of ILTS, ELITA and LICAGE 2014. Roger Williams, Institute of Hepatology/Foundation for Liver Research, London, UK. Medical care after acute liver failure… read more.
Re-transplantation is the only option available for salvaging a failed abdominal graft. As the outcomes after primary transplantations continue to improve, even with the increasing use of extended-criteria… read more.
by Bruce Sylvester – Nine thousand clinicians gathered at the 2013 annual meeting of the European Association for the Study of the Liver/International Liver Congress in Amsterdam on… read more.
Hepatitis C patients treated with Merck’s investigative MK-5172, an oral NS3/4A protease inhibitor, combined with 24 or 48 weeks of peginterferon alfa 2b (Pegasys/ Roche) and ribavirin (Ribasphere/… read more.
C. difficile is a bacterium that is common in the environment. According to the Center for Disease Control and Prevention, approximately 337,000 cases of CDI are reported each… read more.
by Thomas R. Collins – The state of treatment for Hepatitis C patients waiting for a liver transplant leaves a lot to be desired
by Bruce Sylvester – Researchers from a Phase III study report no difference in rates of viral clearance between two anemia management strategies for patients with chronic hepatitis… read more.
by Bruce Sylvester – Two studies presented at EASL suggest the real human and economic costs of liver disease across Europe.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
